NuroKor Limited

Idea

Introduction

Since 2018, NuroKor has harnessed bioelectronic technology for pain management, recovery, and physical performance.

Our goal is to disrupt the clinical and consumer markets with our groundbreaking KorOS treatments and ultra-wearable technology. Our formulations are non-invasive, highly effective and include patent-pending multiwave microcurrent. Successful and impactful, we are committed to developing effective products with a unique value proposition.

Our ambition is to grow and create specialised verticals for anaesthetics, wound care, and aesthetics.

With sales already in 10 countries, we are expanding to strengthen our presence and bring improved quality of life to consumers globally.

Substantial accomplishments to date

Monetisation strategy

- Currently, revenue is generated through our 1st generation LifeTech technology.

- Our aim for the next generation of our human technology is to feature app-based adaptive algorithm software with integrated recurring revenue subscription. The first stage of this activity is to design the data collection template as this will allow us to gather test data for data scientists to create machine learning algorithms which will be embedded into the next gen devices.

- Our Animal HealthTech vertical is releasing the next generation equine technology and is in pre-launch.

- We are receiving orders in the USA for clinical distribution in the prescription chronic pain market. For that, we have a sales and reimbursement strategy.

- Healthy product margins help us to provide distributors, wholesalers and resellers with attractive revenue streams. Building on our growing sales channels and user base, we will add to those margins with recurring subscriptions and consumables.

- Growth opportunities exist by scaling distribution and entering new sector markets. Two new international territories will be added to the current six.

Use of proceeds

NuroKor is developing next-generation technology designed to be hyper-personalised, bespoke, and miniaturised.

Funds raised will be used to explore new avenues of research and development, data collection & analysis - essential for refining algorithms and treatment modes.

Further patient trials will be conducted to gain new clinical approvals providing critical information for design optimisation.

As we expand, NuroKor will employ additional expertise to take products from concept to production.

Our platform technology is designed for optimal functionality and scalability supporting numerous sub-brands. This will strengthen our global identity while maximising sales potential across all channels via the latest digital strategies focused on customer experience.

A portion of the investment reflected in this campaign was received by the Company in the 6 months prior to the launch of the investment round on Seedrs and the Company has started putting this to use.